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Abstract
Indium-tin oxide (ITO) is used to make transparent conductive coatings for touch-screen and 
liquid crystal display electronics. Occupational exposures to potentially toxic particles generated 
during ITO production have increased in recent years as the demand for consumer electronics 
continues to rise. Previous studies have demonstrated cytotoxicity in vitro and animal models have 
shown pulmonary inflammation and injury in response to various indium-containing particles. In 
humans, pulmonary alveolar proteinosis (PAP) and fibrotic interstitial lung disease have been 
observed in ITO facility workers. However, which indium materials or specific processes in the 
workplace may be the most toxic to workers is unknown. Here we examined the pulmonary 
toxicity of three different particle samples that represent real-life worker exposures, as they were 
collected at various production stages throughout an ITO facility. Indium oxide (In2O3), sintered 
ITO (SITO) and ventilation dust (VD) particles each caused pulmonary inflammation and damage 
in rats over a time course (1, 7 and 90 days post-intratracheal instillation), but SITO and VD 
appeared to induce greater toxicity in rat lungs than In2O3 at a dose of 1 mg per rat. Downstream 
pathological changes such as PAP and fibrosis were observed in response to all three particles 90 
days after treatment, with a trend towards greatest severity in animals exposed to VD when 
comparing animals that received the same dose. These findings may inform workplace exposure 
reduction efforts and provide a better understanding of the pathogenesis of an emerging 
occupational health issue. Published 2015. This article is a U.S. Government work and is in the 
public domain in the USA.
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Introduction
Indium-tin oxide (ITO) is used as a transparent conductive coating in the manufacture of 
electronics such as touch-screen phones, liquid crystal displays (LCD) and solar panels. To 
achieve the final product, an ITO tile that can be used to make ‘thin film’ coatings, indium 
oxide (In2O3) and tin oxide (SnO2) are mixed in a 90:10 ratio (wt:wt) and fired at high 
temperatures to sinter the ITO mixture into a solidified tile (Udawatte and Yanagisawa, 
2001; Kim et al., 2002). Recently, the demand for ITO has increased as the production of 
consumer electronics continues to expand.
The expansion of the ITO industry has resulted in the emergence of indium lung disease, an 
occupational illness that has affected workers exposed to indium-containing compounds. 
Cases of lung disease in indium-exposed workers began to be reported in the medical 
literature in 2003 (Homma et al., 2003; Cummings et al., 2012). In terms of pulmonary 
symptoms and signs, workers exposed to indium-containing particles by inhalation develop 
a cough, dyspnea, and abnormalities on pulmonary function tests and chest computed 
tomography (CT) scans (Homma et al., 2003; Omae et al., 2011; Cummings et al., 2012). 
Epidemiologic investigation in plants with cases of indium lung disease have demonstrated 
elevated serum biomarkers of interstitial lung disease and functional and radiographic 
abnormalities in co-workers (Chonan et al., 2007; Hamaguchi et al., 2008; Nakano et al., 
2009; Cummings et al., 2013; Cummings et al., 2014).
A recent comprehensive clinical analysis of 10 reported cases, including two from an ITO 
production facility in the United States, demonstrated that workers presented with 
pulmonary alveolar proteinosis (PAP) (within 6–14 months of starting work) or fibrotic 
interstitial lung disease with or without emphysema (within 2–14 years of starting work) 
(Cummings et al., 2012). The current study and our previous studies (Badding et al., 2014b; 
Badding et al., 2015) have utilized particles collected from this same US facility at various 
stages in the ITO production process. These samples are in the micron size range and 
include In2O3, particles generated during the grinding of sintered ITO (SITO) tiles, and 
dusts generated during the reclamation of indium from production waste materials and spent 
tiles (ventilation dust). Thus, we were able to expose rats to the same particles that workers 
may encounter throughout the ITO production process.
Previous studies of indium-containing particles have demonstrated toxicity in vitro (Lison et 
al., 2009; Gwinn et al., 2013; Badding et al., 2014b; Badding et al., 2015) and pulmonary 
inflammation in rodent models (Lison et al., 2009; Tanaka et al., 2010; Nagano et al., 
2011a, b; Lim et al., 2014; Gwinn et al., 2015). Rat and mouse studies of ITO intratracheal 
instillation or inhalation demonstrated significant pulmonary changes, including 
inflammatory cell infiltrates, alveolar proteinosis and interstitial fibrosis (Tanaka et al., 
2010; Nagano et al., 2011a, b). In some studies, ITO was shown to be more toxic and induce 
more lung damage than In2O3 (Lison et al., 2009; Nagano et al., 2011a, b). However, 
indium phosphide particles, which are composed of indium that is relatively more soluble 
than indium found in ITO, were shown to be more toxic than ITO in one study (Gwinn et 
al., 2015).
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In vitro studies from our lab and others suggest that macrophages play a role in the toxicity 
of indium-containing particles and that pulmonary epithelial cells are also sensitive to these 
exposures. Our recent findings suggest that both cell types have proinflammatory responses 
when exposed to SITO particles (Badding et al., 2015). Additionally, we found that 
macrophage uptake of SITO or dust collected from the ventilation system in the indium 
reclamation department of the facility (ventilation dust) impaired subsequent phagocytosis 
of Escherichia coli, implicating macrophage dysfunction from these exposures (Badding et 
al., 2015).
The main goal of this study was to determine the adverse pulmonary effects of various 
respirable particles found in an ITO production facility. Given that the particles were 
collected from the starting materials, ITO grinding, and indium reclaim departments, we 
wanted to determine whether a particular stage or process puts workers at higher risk for 
developing indium lung disease. Our findings suggest that all three particle types cause 
proinflammatory responses and lung damage to varying degrees, but that dust from the 
reclaim department (ventilation dust) may be the most hazardous to workers.
Materials and methods
ITO production particles
The particles used in this study were collected at a United States ITO production facility 
from containers of feedstock materials or production processes (NIOSH, 2012). Indium 
oxide (In2O3) is from the refinery, sintered ITO (SITO) is from the ITO department’s 
grinding area; and ventilation dust (VD) is from the reclamation department where indium 
metal is reclaimed from waste materials. The particles have been previously characterized 
and evaluated for toxicity in vitro (Badding et al., 2014b). SITO had been in contact with 
metalworking fluid and was found to have low levels of endotoxin present, but was still 
found to be cytotoxic when endotoxin activity was removed with heat (Badding et al., 
2015). The In2O3 is crystallographically pure and the other two samples are mixtures. SITO 
is 44% O, 19% C, 24% In, and 2.7% Sn, and VD is 21% O, 49% C, 12% In, and 0% Sn 
(atom % at particle surface by X-ray photoelectron spectroscopy). The mean aerodynamic 
diameters are 2.7 ± 2.2 μm for In2O3, 1.2 ± 0.8 μm for SITO and 0.5 ± 0.3 μm for VD 
(Badding et al., 2014b).
Animals
Male Sprague–Dawley [Hla:(SD) CVF] rats from Hilltop Lab Animals (Scottdale, PA, 
USA), weighing 270–330 g were used for all exposures. Animals were acclimated for at 
least 7 days after arrival and housed under a standard 12-h day/night cycle at 20–25 °C. 
They were provided HEPA-filtered air, irradiated Teklad 2918 diet and tap water ad libitum. 
Animal facilities are specific pathogen-free, environmentally controlled and accredited by 
the Association for Assessment and Accreditation of Laboratory Animal Care International 
(AAALAC). All animal procedures used in the study were reviewed and approved by the 
NIOSH Animal Care and Use Committee.
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Intratracheal particle instillation
The particles were suspended in sterile, endotoxin- and Ca2+, Mg2+-free phosphate-buffered 
saline (PBS), pH 7.4. Rats were lightly anesthetized by an intraperitoneal injection of 30–40 
mg kg−1 body weight sodium methohexital (Brevital, Eli Lilly, Indianapolis, IN, USA) and 
intratracheally instilled with 1.0 and 5.0 mg rat−1 In2O3 or SITO in 300 μl of sterile PBS. 
For VD, rats received 0.5 and 1.0 mg rat−1 owing to the mortality at 5.0 mg rat−1. For each 
condition (particle sample and time point), animals were intratracheally instilled with 300 μl 
of sterile PBS as vehicle controls (0 mg). Dosages were determined using the recommended 
exposure limit (REL) for Indium (0.1 mg m−3), ventilation rate (9.6 m3 day−1) and 
deposition fraction (0.2). For lung burdens of 0.5, 1 and 5 mg, it would take 2.5, 5 and 25 
work years (260 days year−1), respectively, to reach those amounts (considering 
normalization for rat body weights and lung surface area).
Bronchoalveolar lavage
At 1, 7 and 90 days post-intratracheal instillation (IT), bronchoalveolar lavage (BAL) was 
performed. Animals were euthanized with an intraperitoneal injection of sodium 
pentobarbital (>100 mg kg−1 body weight; Sleepaway. Fort Dodge Animal Health, Wyeth, 
Madison, NJ, USA) and exsanguination. A tracheal cannula was inserted, and the lungs were 
lavaged with 6 ml of ice-cold endotoxin- and Ca2+, Mg2+-free PBS (pH 7.4). The recovered 
BAL fluid (BALF) was centrifuged at 650 g for 10 min at 4 °C, and the resultant cell-free 
supernatant was transferred to tubes for analysis of lung injury and inflammatory 
parameters. The cell pellets from each rat were resuspended in 1 ml of PBS and evaluated as 
described below.
Evaluation of cells and lung injury from BALF
The total cell numbers, alveolar macrophages and polymorphonuclear leukocytes (PMNs) 
recovered by BAL were determined using a Beckman Coulter Multisizer 4 Analyzer 
(Beckman Coulter Indianapolis, IN, USA). Cells were differentiated using a Cytospin 3 
centrifuge (Shandon Life Sciences International, Cheshire, England). Cell suspensions (1 × 
105 cells) were spun for 5 min at 72 × g and pelleted onto a slide. The cytospin preparations 
were stained with modified Wright–Giemsa stain, and cell differentials were determined by 
light microscopy. Differential cell counts were calculated by multiplying the total cell counts 
(~200 per rat) by the cell differential percentage obtained from the cytospin preparations. 
Using the acellular fraction of BALF, lactate dehydrogenase (LDH) activity, an indicator of 
general cell damage and toxicity, was measured. LDH activity was determined by measuring 
the oxidation of lactate to pyruvate coupled with the formation of NADH at 340 nm. 
Measurements were performed with a COBAS C111 auto-analyzer (Roche Diagnostics 
USA, Indianapolis, IN, USA).
Phagocytosis assay
After counts from BALF, the cell suspensions were centrifuged again, and pellets were 
resuspended at the desired macrophage concentration of 1 × 106 cells ml−1 in minimal 
essential medium (MEM) with Eagle’s salts, 10% fetal bovine serum and 50 mg ml−1 
penicillin/streptomycin (Invitrogen Life Sciences, Grand Island, NY, USA). Cells were then 
Badding et al. Page 4
J Appl Toxicol. Author manuscript; available in PMC 2016 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
plated at 2.5 × 105 macrophages per well in 96-well dishes and incubated at 37 °C in a 5% 
CO2 incubator for 1 h to allow attachment. Cells were washed three times with medium to 
remove the unattached (and non-phagocytic) cells. A previous study by our group 
demonstrated that plated cells recovered from rat BAL are predominantly macrophages, 
even after silica particle treatments (Antonini et al., 2000). Therefore, the remaining 
adherent cells used in the assay were mostly macrophages, although small amounts of other 
phagocytes (PMNs) may have been attached as well.
The pHrodo™ Red E. coli BioParticles® were prepared according to manufacturer’s 
instructions (Molecular Probes, Carlsbad, CA, USA), and the assay was carried out as 
previously described (Badding et al., 2014a). These particles allow specific detection of 
phagocytosed particles versus adherent and extracellular particles, as a result of the pH-
sensitive fluorogenic dye. Briefly, wells were washed again prior to the addition of 
BioParticle suspensions to all wells, including blanks (no cells) to be subtracted from all 
experimental wells. After incubation for 2 h at 37 °C, plates were read at 560 nm 
excitation/600 nm emission to measure changes in fluorescence. All conditions were run in 
triplicate wells and macrophages from at least four rats per condition were used. 
Cytochalasin D (Sigma-Aldrich, St. Louis, MO, USA) at a final concentration of 10 μM was 
used as a positive control to inhibit phagocytosis in a second set of wells containing 
macrophages from PBS vehicle control-treated rats. The percentage of maximal 
phagocytosis was calculated as a ratio of the net experimental phagocytosis to the 
phagocytosis by the PBS control group (0 mg).
Enzyme-linked immunosorbent assay (ELISA)
BALF from each rat was frozen at −80 ° C. Cytokine levels were measured with ELISA kits 
(rat IL-6; cat. no. ER3IL65, rat IL-1β; cat. no. ER2IL1B, rat TNF-α; cat. no. ER3TNFA; 
Thermo Scientific, Rockford, IL, USA) according to manufacturer’s instructions. All 
conditions were run in duplicate wells.
Plasma indium determination
Whole blood was collected for indium content analysis via the abdominal aorta into BD 
Vacutainer tubes (cat. no. 368381, K2 EDTA plastic royal blue top; BD, Franklin Lakes, NJ, 
USA), which led to exsanguination after sodium pentobarbital injection. Blood tubes were 
immediately placed on a rocker for 10 min, followed by centrifugation for 10 min using a 
refrigerated centrifuge (Sorvall Legend XTR). The resulting plasma supernatant was 
immediately transferred to a clean polypropylene tube using a Pasteur pipette. The samples 
were frozen at −80 °C, then shipped on dry ice to NMS Labs (Willow Grove, PA, USA) for 
plasma indium analysis using inductively coupled plasma mass spectrometry (ICP-MS) with 
a 0.03 mcg l−1 limit of detection.
Histopathological analysis
At 90 days post-exposure, formalin-fixed sections of lung from 35 animals were stained 
with Hematoxylin and eosin (H&E) and Picrosirius Red and evaluated microscopically for 
evidence of inflammation, alveolar proteinosis and interstitial fibrosis. The left lung was 
examined for each animal. To follow diagnostic terminology and procedures used in 
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previous studies (Shackelford et al., 2002; Mann et al., 2012), each microscopic change was 
scored for severity according to the following parameters: 1 = minimal, 2 = mild, 3 = 
moderate, 4 = moderately severe, and 5 = severe. Statistical analysis was not performed 
owing to the small numbers of animals used for each group (n = 3–5).
Statistical analysis
All data are represented as the mean ± SEM for each condition. One-way and two-way 
analysis of variance tests with Tukey or Dunnett’s post-tests were performed using 
GraphPad Prism 6 software (GraphPad Software, Inc., La Jolla, CA, USA) for each 
experiment to compare the responses between groups, and statistical significance is shown 
when P < 0.05.
Results
Parameters of bronchoalveolar lavage
The instilled particles used in this study included one of the starting materials (In2O3), 
particles generated during grinding and cutting of sintered ITO tiles (SITO), and ventilation 
dust (VD) collected from the indium reclaim department, which also contains SITO as well 
as other forms of indium (Badding et al., 2014b). These samples represent potential particle 
exposures in different parts of the facility. To evaluate pulmonary damage and inflammation 
in the lungs of rats after intratracheal instillation (IT) of these particles, bronchoalveolar 
lavage (BAL) was performed. The BAL fluid (BALF) analyzes indicate that each particle 
type induced pulmonary toxicity, but to varying degrees and with differing amounts of cell 
infiltration and pulmonary damage (Fig. 1). The higher doses of SITO and VD were 
associated with the greatest LDH values on day 7 post-IT (Fig. 1A). This was dramatically 
reduced by day 90 in the BALF of VD-treated rats, but persisted in SITO-treated rat BALF 
and continued to rise in 1 mg-treated SITO rats.
Cell counts from SITO-treated rat lungs at both doses drastically increased from day 1 to 7 
and continued through day 90 post-treatment (Fig. 1B). In2O3 treatment induced a similar 
trend of increasing cell counts, but at much lower levels than with SITO treatment. In fact, 
only the 5-mg dose of In2O3 caused significant changes in the BALF parameters measured 
over PBS vehicle control rats, but the counts were still lower than those from 1 mg SITO-
treated rats. Treatment with VD also resulted in significantly elevated cell counts, but the 
number of recovered cells was reduced in the day 90 BALF. It is important to note that at 
day 7, 1-mg VD and 5-mg SITO induced similar levels of LDH and cell counts recovered 
from BAL.
Cell differential analysis demonstrated that cells in rat lungs were mostly PMNs and 
macrophages following treatments with all three particle samples (Fig. 2). The results for 
each particle type appear very similar between days 1 and 7, with shifts in cell percentages 
(from predominantly PMNs to macrophages) occurring at day 90 for In2O3 and VD (Fig. 
2C). However, cells from SITO-exposed rats maintained very similar cell differentials by 
day 90 (still mainly PMNs). In contrast, 1-mg In2O3 treatment caused a much lower 
percentage of PMN infiltrates compared with 1-mg SITO or VD, and BALF from the 5-mg 
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In2O3 exposure had a lower percentage of PMNs compared with 5-mg SITO at all time-
points.
Cytokine production
Cytokines measured from cell-free BALF show a proinflammatory response in the lungs of 
treated rats (Fig. 3). TNF-α was only significantly elevated with SITO treatment at day 1 
post-IT with the 5-mg dose, whereas IL-6 and IL-1β were elevated with various treatments 
and at multiple time points. IL-6 was not induced by In2O3 under any condition. Cell-free 
BALF from SITO-treated rats contained measurable IL-6 with both doses, but it was only 
statistically significant for the 5-mg treatment group and at early time-points (Fig. 3B). Both 
doses of VD-induced elevated IL-6 at the earlier time-points as well. For IL-1β, all particles 
and doses induced elevated levels on day 1. BALF from rats treated with SITO and VD had 
persistently high IL-1β out to 90 days post-exposure (Fig. 3C).
Assessment of BAL macrophage phagocytosis
Indium lung toxicity has been associated with PAP (Cummings et al., 2010; Cummings et 
al., 2012). Phagocytic dysfunction in macrophages is thought to be a cause of this build-up 
of surfactant and other proteins in the lung (Kitamura et al., 1999; Greenhill and Kotton, 
2009). To examine whether particle instillations affected the phagocytic ability of lavaged 
alveolar macrophages, an assay was employed to evaluate subsequent particle uptake 
outside of the lung. In this assay, phagocytic cells from BALF were plated (controlling for 
macrophage numbers) and exposed to pH-sensitive E. coli particles that fluoresce when 
properly phagocytosed. Macrophages isolated from 1-mg In2O3 rats on day 7 post-IT 
showed a slight but significant enhancement in average phagocytic ability compared to 
macrophages from rats exposed only to the vehicle control, but this effect was not observed 
at the higher dose (130.3 ± 15.3% 1 mg vs. 73.7 ± 7.8% 5 mg In2O3, mean ± SEM) (Fig. 
4A).
In contrast, macrophages isolated from rat lungs 7 days post-treatment with SITO 
demonstrated a decrease in the average phagocytic ability at both doses (49.1 ± 1.1%, 1 mg 
and 19.1 ± 1.4%, 5 mg SITO, mean ± SEM) (Fig. 4A). This effect was as potent as 
pretreating a group of vehicle control cells with Cytochalasin D, a known inhibitor of 
phagocytosis. Similar to the SITO groups, macrophages from VD-treated rat lungs were 
very ineffective at E. coli particle phagocytosis 7 days post-IT (36.6 ± 2.1%, 0.5 mg and 
11.1 ± 1.9%, 1 mg VD, mean ± SEM) (Fig. 4A). These effects appeared to resolve by 90 
days post-IT. In fact, cells from day 90 1-mg VD rats had enhanced phagocytosis over 
controls (146.3 ± 9.0% 1-mg VD, mean ± SEM). This was the only significant difference 
noted at day 90.
Plasma indium concentrations
Current exposure assessment for workers handling indium-containing materials involves 
measuring blood indium concentrations. Whether or not this is an accurate predictor of 
current exposures or lung disease remains to be determined (Omae et al., 2011; Liu et al., 
2012). Thus, an aim of our study was to evaluate indium in the plasma throughout the time-
course. Plasma from rats treated with 1-mg In2O3 contained very little indium, whereas the 
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higher dose showed a time-dependent increase in indium concentration (Fig. 5). However, 
these values were still low (<2 mcg l−1). Similarly, SITO induced increases in plasma 
indium over the time course, and this effect was more dramatic with the 5-mg dose. In fact, 
between days 1 and 90, 5-mg SITO-derived plasma indium concentrations increased 6.8-
fold (12.5 ± 0.6 mcg ml−1 D1 vs. 85.3 ± 7.7 mcg l−1 D90 SITO, mean ± SEM).
Interestingly, plasma indium from VD-treated rats displayed different kinetics compared 
with In2O3 and SITO, as it peaked on day 7 (Fig. 5). Whether concentrations were further 
elevated past day 7 but prior to day 90 is unknown, as plasma indium concentrations were 
not measured on days 8 to 89. It is also intriguing that 1-mg VD at day 7 caused plasma 
indium levels comparable to 5-mg SITO at day 90 (93.5 ± 19.2 mcg ml−1 1-mg VD vs. 85.3 
± 7.7 mcg l−1 5-mg SITO, mean ± SEM). A possible explanation is the presence of different 
forms of indium on the surface of each particle type.
Pulmonary histopathology findings
Hematoxylin and eosin (H&E) and Picrosirius Red stained sections of lung from animals 
were evaluated microscopically for evidence of inflammation, alveolar proteinosis (PAP) 
and interstitial fibrosis 90 days post-exposure. The incidence and mean severity of the 
microscopic findings for each group are summarized in Table 1. The analysis was carried 
out primarily to determine the relative severity of the lesions among treatment groups. 
Chronic bronchiointerstitial pneumonia was seen in the lungs of all exposed animals 
examined. Histologically, these changes were characterized by the presence of increased 
numbers of macrophages admixed with fewer neutrophils within alveolar walls and alveolar 
spaces, often centered on terminal bronchioles. Other microscopic changes included 
prominent type II pneumocyte hypertrophy and hyperplasia (Fig. 6B), pleural inflammation 
and fibrosis, and variable amounts of alveolar exudation consistent with PAP (Fig. 6B, C). 
Interstitial fibrosis, seen as increased amounts of red-staining fibrillar collagen in Picrosirius 
Red-stained sections of lung, was frequently observed in exposed animals (Fig. 6E, F). 
Fibrotic changes tended to be most prominent in areas of inflammation and type II 
pneumocyte hyperplasia, suggesting deposition of collagen in response to pulmonary injury 
and repair.
The severity of fibrotic and inflammatory changes in the lung ranged from minimal to 
severe depending on the particle type and dose. Interestingly, proteinosis tended to be more 
severe in the lungs of animals exposed to 5 mg of SITO (Fig. 6C), despite the fact that the 
majority of these animals had mild pathology. Overall, the pathology was most severe in 
lungs of animals exposed to VD, despite exposure to a lower particle dose when compared 
with SITO or In2O3.
Discussion
The increased use of indium-containing materials in manufacturing has caused concern for 
workers exposed to these particles in their occupational environment. In the last decade or 
so, there have been multiple case reports of workers in the ITO industry developing severe, 
sometimes fatal, lung disease. As the industry continues to expand, the pathogenesis of 
indium lung disease merits investigation.
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Intratracheal instillation of ITO production particles in this study caused significant lung 
damage and inflammation. In general, particles containing sintered ITO (SITO and VD) 
were more toxic than the pure In2O3 particles. The reason for this is unclear, but our 
findings agree with previous pulmonary rat studies where ITO particles induced more 
inflammation and damage than In2O3 (Lison et al., 2009; Nagano et al., 2011a, b; Lim et al., 
2014). The damage and inflammation induced by In2O3 (according to BALF parameters) 
was delayed compared with the other two particle types. Although compositionally different, 
all three samples have In2O3 on their particle surfaces as previously characterized (Badding 
et al., 2014b). Thus, the presence of In2O3 is likely not the sole pneumotoxic entity of these 
particles.
Indium salts, which are present on VD particles, are known to be significantly more soluble 
than In2O3 (A. Stefaniak, personal communication). This would make dissolution of indium 
ions from VD particles more rapid than the other particle types. The enhanced solubility of 
this form of indium from VD may influence the toxic effects seen in our study. Besides 
being used at a lower dose (0.5 mg), VD particles also contain less total surface indium on a 
per mass basis (12% VD versus 24% for SITO) and yet are equally, if not more, toxic to rat 
lungs. This further enhances the suggestion that greater indium solubility may influence 
particle toxicity. Gwinn et al. (2015) recently demonstrated that solubilization of ionic 
indium from particles engulfed by macrophages correlated with in vitro macrophage 
cytotoxicity and in vivo pulmonary toxicity. Specifically, they showed that soluble InCl3 (an 
indium salt) caused much greater cytotoxicity in cultured macrophages than less soluble 
forms of indium.
Measurements of indium in the blood plasma suggest that some of the metal did, in fact, 
move out of the lung. One scenario in which this may have occurred is the release of indium 
ions from particles within the lung to the blood. Another could be extravasation of particles 
from the lung due to tissue injury, which then release indium outside of the lung. Other 
studies have revealed indium elimination from the lung and distribution throughout the 
blood and lymph nodes (Nagano et al., 2011a, b) and other organs such as the spleen, liver, 
brain (Lim et al., 2014) after ITO pulmonary exposures. Two studies by Nagano et al. 
(2011a, b) showed that 13-week inhalation exposures in both rats and mice led to higher 
blood indium concentrations with ITO compared with In2O3, which our findings in Fig. 5 
confirm. Plasma indium was highest at 7 days post-IT for VD, as opposed to 90 days with 
In2O3 and SITO. Given that we only measured blood indium at three-time points (and none 
between 7 and 90 days), the peaks may have been different for these samples. However, in 
general, indium dissolution from VD particles appeared to occur more rapidly than the other 
particle types. Whether this is indicative of more severe pulmonary damage and overall 
toxicity as a biomarker is unknown, but the plasma indium concentrations seemed to 
correlate with the extent and timing of pulmonary damage and inflammatory cell infiltrates. 
For example, plasma indium was highest when LDH and cells in BALF were highest (at day 
7 for VD vs. day 90 for SITO and In2O3) (Figs. 1 and 5).
BALF parameters for rats treated with In2O3 or SITO revealed increasing, and persistent 
elevations in LDH and inflammatory cell infiltrates over a 90-day time course; although this 
was less severe for In2O3 treatments (Fig. 1). In contrast, VD-treated rats showed a robust 
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initial increase in BALF parameters, followed by decreased LDH and recovered 
inflammatory cells at 90 days post-IT. These parameters were still significantly elevated 
compared to the vehicle controls, but less than the day 7 BALF findings. However, the 
cellularity seen with histology in day 90 VD-treated rats (Fig. 6B) suggests that 
inflammation persisted in the lungs with these treatments. In cases where alveoli contain 
activated macrophages, such as what was seen in animals exposed to VD, these 
macrophages are large and stick to alveolar walls and are not easily removed from the lung 
with BAL. This phenomenon has been observed in previous studies, resulting in fewer cells 
recovered from lavage (Porter et al., 2007).
The comparisons among particle types are flawed by the fact that the high dose of VD was 1 
mg versus 5 mg for In2O3 and SITO. However, if we just compare the 1-mg BALF results, 
VD-induced more LDH release into BALF than the other particle types at day 7 (Fig. 1A). 
AlThough, there was no difference in cell counts between 1 mg treatments of SITO or VD at 
this time point. By day 90, LDH in the 1 mg SITO rat BALF was higher than the 1 mg VD 
group, and total recovered cells in the 1 mg SITO exceeded that of VD. Thus, it is difficult 
to say whether SITO or VD was more overtly toxic to the rats’ lungs at a 1 mg dose by 
strictly examining the BALF.
Cytokines are another indicator of inflammation in the lungs of treated rats. Figure 3 further 
demonstrates the presence of a proinflammatory response by SITO and VD exposures. 
Elevated IL-6 and IL-1β in the BALF of SITO and VD-treated rats may be initiating factors 
in the development of fibrotic lesions (seen in day 90 lungs). Strong clinical evidence has 
implicated IL-6 in fibrosis development, as patients with idiopathic pulmonary fibrosis have 
elevated IL-6 in their BALF ( Jones et al., 1991; Takizawa et al., 1997). A study utilizing an 
IL-1 receptor antagonist in mice treated with bleomycin or silica demonstrated the strong 
influence of this cytokine in lung fibrogenesis (Piguet et al., 1993). Another study used gene 
transfer to overexpress IL-1β in rat lungs to elicit a pro-fibrotic response (Kolb et al., 2001). 
Thus, our histopathological findings of fibrosis in regions of lung inflammation (Fig. 6) 
suggest that a long-term consequence of ITO exposure-induced cytokine release, and 
inflammation is scarring. Similarly, clinical cases of workers in the ITO industry have 
revealed that pulmonary fibrosis sometimes occurs as a result of indium-containing particle 
exposures (Cummings et al., 2012). Further, a recent study from our lab demonstrated the 
ability of SITO and VD to induce inflammasome activation and subsequent IL-1β release 
from macrophages in vitro (Badding et al., 2015). Here, the cytokine measurements from rat 
BALF confirm that IL-1β release occurs in vivo as well (Fig. 3C).
One of the most intriguing findings was the altered phagocytic ability of pulmonary 
phagocytes isolated from rats treated with SITO or VD particles in Fig. 4. Whether the 
decrease was due to macrophage impairment (possibly in response to particle overload) or a 
change in the mononuclear cell population recovered in the BALF is unclear. Under 
conditions of pulmonary inflammation, some monocyte phenotypes can have lower 
phagocytic activity than normal resident alveolar macrophages (Brittan et al., 2014). Thus, 
the influx and/or proliferation of macrophage populations within the lung following particle 
exposures may have differential effects on subsequent pathogen uptake. We previously used 
this same assay to show that pre-uptake of SITO or VD caused reduced E. coli phagocytosis 
Badding et al. Page 10
J Appl Toxicol. Author manuscript; available in PMC 2016 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
in the transformed mouse macrophage cell line, RAW 264.7 (Badding et al., 2015). A 
clinical outcome of indium compound exposure in ITO workers is PAP, which is thought to 
be as a result of macrophage dysfunction (Kitamura et al., 1999; Greenhill and Kotton, 
2009). Therefore, the implications of our results are that cellular uptake of indium-
containing particles may lead to the altered phagocytic function of lung macrophages, 
leading to excess surfactant. These results suggest a potential mechanism for PAP 
pathogenesis in ITO workers. Whether these exposures lead to increased susceptibility of 
workers to pulmonary infections is not known, but may deserve further investigation.
Signs of PAP, such as alveoli filled with lipoprotein material, were evident in the lungs of 
animals treated with all three particle types. The mean severity of PAP was greater than 
fibrosis in animals treated with SITO (PAP: 4.3 vs. fibrosis: 3.3, 5 mg SITO), whereas these 
two endpoints were roughly the same for animals treated with In2O3 (e.g. PAP: 3 vs. 
fibrosis: 3.2, 5 mg In2O3). In workers with indium lung disease, PAP tends to develop prior 
to fibrosis (within 6–14 months of hire for PAP vs. 2–14 years of hire for fibrosis) 
(Cummings et al., 2012). This has been seen in other rat studies as well (Nagano et al., 
2011a, b). Thus, early damage and inflammation seemed to induce fibrotic changes, which 
indicate long-term consequences of an initial bolus exposure.
In general, the present study demonstrated that particles generated during the grinding of 
SITO tiles and the reclamation of indium (VD) were toxic to rat lungs. This was reflected in 
pulmonary changes involving significant inflammation, alveolar protein accumulation, and 
scarring. These changes have also been seen in case studies of workers in the ITO industry 
who develop indium lung disease. Our findings here and in a previous study suggest that 
altered phagocyte function following particle exposures may play a role in the pathogenesis 
of indium lung disease. With ITO production on the rise, workers who handle indium-
containing particles should be monitored for changes in lung health and blood indium.
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Figure 1. 
Lactate dehydrogenase (LDH) levels and inflammatory cell counts in rat bronchoalvelolar 
lavage fluid (BALF) over a time course of 90 days post-exposure. (A) LDH concentration in 
BALF from days 1, 7, and 90 post-IT of particle suspensions. In2O3 (circles), SITO 
(squares), and VD (triangles) symbols represent the mean ± SEM (n = 6–8 rats). From the 
same BALF, (B) total cells, (C) macrophages and (D) PMNs were counted. (Note: PMNs 
were not counted on day 1 for SITO). *P < 0.05 compared with phosphate-buffered saline 
(PBS) vehicle controls (0 mg) on that day.
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Figure 2. 
Cell differentials from bronchoalvelolar lavage fluid (BALF) over a time course of 
exposure. Cells from (A) day 1, (B) day 7 and (C) day 90 rats were designated as 
macrophages, PMNs, lymphocytes, or eosinophils (200 cells rat−1). The percentage of cells 
scored as each cell type was calculated, and bars represent the mean percentage ± SEM (n = 
6–8 rats).
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Figure 3. 
Cytokine concentrations in bronchoalvelolar lavage fluid (BALF). Concentrations of (A) 
TNF-α, (B) IL-6 and (C) IL-1β were measured in BALF from In2O3, SITO and VD-treated 
rats. *P < 0.05 compared with the 0-mg controls on that day.
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Figure 4. 
Phagocytosis of Esherichia coli by bronchoalvelolar lavage fluid (BALF) phagocytes. Cells 
from the BALF of (A) day 7 or (B) day 90 rats were plated at 2 x 105 macrophages/well, 
washed to remove unattached cells, and treated with pHrodo™ Red E. coli BioParticles® 
for 2 h to allow phagocytosis. A separate set of plated control cells (0 mg) received 
Cytochalasin D (Cyto D) to prevent phagocytosis. Plates were read to measure changes in 
fluorescence, and values were normalized to the phosphate-buffered saline (PBS) controls (0 
mg) to represent maximal phagocytosis. Error bars represent the mean ± SEM (n = 4–5 rats). 
*P < 0.05 compared with 0-mg controls.
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Figure 5. 
Plasma indium concentrations over a time-course. Whole blood was collected from rats, and 
plasma indium content measured using inductively coupled plasma mass spectrometry (ICP-
MS). Error bars represent the mean ± SEM (n = 4 rats). *P< 0.05 compared with 0-mg 
controls.
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Figure 6. 
Histopathological findings in rat lungs 90 days post-IT. Lung sections from day 90 rats were 
stained with Hematoxylin and eosin (H&E) and Picrosirius Red and evaluated for 
inflammation, fibrosis and alveolar proteinosis. (A) Photomicrograph of H&E stained 
section of lung from a control animal (200 x magnification). (B) Lung from an animal 
exposed to 0.5-mg VD showing alveoli filled with foamy macrophages (asterisk) and 
alveolar walls lined by hyperplastic type II pneumocytes (arrows) (200 x magnification). (C) 
Alveoli containing abundant eosinophilic material consistent with lipoprotein (asterisk) from 
animal exposed to 5-mg SITO (200 x magnification). (D) Photomicrograph of Picrosirius 
red stained section of lung from a control animal showing normal pattern of collagen 
staining in alveolar walls (400 x magnification). (E) Increased interstitial collagen observed 
in alveolar walls, associated with deposition of particles (arrows) from an animal treated 
with 5 mg of In2O3 (400 x magnification). (F) Lung from an animal exposed to 1 mg of VD. 
Alveolar walls are thickened by fibrosis (arrows) (400 x magnification).
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